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Received June 28, 2010; accepted January 12, 2011AbstractBackground: Our aim here was to explore treatment efficacy of pemetrexed and docetaxel in non-small-cell lung cancer patients who had failed
previous chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor therapy.
Methods: We retrospectively reviewed clinical data of our non-small-cell lung cancer patients who received third- or fourth-line chemotherapy
with pemetrexed or docetaxel in our institution from January 2006 to December 2009.
Results: One hundred and twenty-three patients received treatment, including 85 patients with pemetrexed treatment and 38 patients with docetaxel
treatment. There was no difference in tumor response rate and toxicity profiles when using pemetrexed as third- or fourth-line treatment, neither was
there difference in docetaxel treatment of third- versus fourth-line treatment. There was also no difference between docetaxel and pemetrexed in
response rate and control rate when they were used as fourth-line treatment. However, docetaxel used in fourth-line treatment had higher incidence
of neutropenia and more frequent need of granulocyte colony-stimulating factor support compared with pemetrexed in fourth-line treatment.
Median progression-free survivals (PFSs) were 2.6 months and 3.8 months when using pemetrexed as third- and fourth-line treatment, respectively
( p ¼ 0.417). Median PFSs were 3.8 months and 4.8 months when using docetaxel as third- and fourth-line treatment, respectively ( p ¼ 0.882).
There was also no difference in PFS between pemetrexed and docetaxel, both in third- and fourth-line treatment. Median survivals were 13.4, 12.2,
13.2, and 13 months for pemetrexed in third-line, fourth-line, and docetaxel in third-line and fourth-line treatment, respectively.
Conclusion: This retrospective study of pemetrexed and docetaxel showed relatively safe toxicity profile, reasonable response rate, and long
survival when used as third- and fourth-line chemotherapy. Thus, it is reasonable to give good performance status patients third- and fourth-line
chemotherapy. A phase III randomized trial is needed for better clarification of these issues.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Third-generation anti-cancer drugs and their combination
with platinum have shown better response rates and survival
than conventional regimens during the last two decades, and* Corresponding author. Dr.Yuh-MinChen,ChestDepartment, TaipeiVeterans
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doi:10.1016/j.jcma.2011.03.005this kind of doublet treatment has been used as standard first-
line treatment of treatment-naı¨ve advanced non-small-cell
lung cancer (NSCLC).1e3 There have been three phase III
randomized studies, including two studies of docetaxel that
showed better survival of NSCLC patients who received
docetaxel as second-line therapy compared with best
supportive care or other chemotherapy,4,5 and one study of
pemetrexed that showed pemetrexed treatment had advantages
in terms of tolerability and quality of life compared withhinese Medical Association. All rights reserved.
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pemetrexed were recommended as standard second-line
chemotherapy for patients with disease progression after first-
line treatment.
Recently, with more frequent usage of epidermal growth
factor receptoretyrosine kinase inhibitors (EGFR-TKI),
because of their relative convenience of use and better toxicity
profiles, as second-line treatment of NSCLC, drugs that were
used previously as second-line chemotherapeutic agents, such
as docetaxel and pemetrexed, have been reserved for third-line
and even fourth-line treatment, after the patient has failed
third-line treatment that used one of two effective second-line
agents.7e9 Because those three phase III randomized studies
that showed better survival of NSCLC patients who received
docetaxel as second-line therapy,4,5 and pemetrexed had
advantages of better tolerability and quality of life than
docetaxel6 were performed before the era of EGFR-TKI,
whether or not docetaxel and pemetrexed still have similar
efficacy in patients who have received two lines of treatment,
including platinum-based chemotherapy and EGFR-TKI
treatment, are unknown and need further investigation.1
In the present study, we retrospectively reviewed our patients’
data to define clinical characteristics, analyze, and compare the
feasibility of using docetaxel or pemetrexed as third-line or
fourth-line chemotherapy after the patients had failed previous
platinum-based doublets and EGFR-TKI therapies.
2. Methods
This retrospective review was approved by the institutional
review board of Taipei Veterans General Hospital (VGHIRB
No. 98-03-10A). We retrospectively reviewed chart records
and case report forms of patients with advanced NSCLC of the
lungs who had progressed after receiving two lines of treat-
ment, including one line of platinum-based doublet and one
line of EGFR-TKI, and received third-line or fourth-line
chemotherapy with docetaxel (60 mg/m2 Day 1 every 3 weeks
for a maximum of 6 cycles; more cycles were allowed in those
patients who responded to the treatment) or pemetrexed
(500 mg/m2 Day 1 every 3 weeks for a maximum of 6 cycles;
more cycles were allowed in those patients who responded to the
treatment) in our department from January 2006 to December
2009. In this retrospective study, EGFR-TKIwas used as second-
line treatment after the patients progressed from first-line plat-
inum-based chemotherapy. Furthermore, only single-agent
pemetrexed or docetaxel was allowed as third-line treatment in
all patients. All patients received standard pre-medications for
their chemotherapy. All patients were Stage IV when they
received present docetaxel or pemetrexed salvage therapy. All
patients had a World Health Organization performance status of
0e2 when starting third- or fourth-line treatment.
The clinical characteristics, response rate, toxicity profiles,
progression-free survival (PFS), and overall survival time were
recorded and analyzed. Treatment-related toxicities were
recorded, based on the National Cancer Institute Common
Toxicity Criteria for Adverse Events (version 3.0). Types of
response were assessed with the use of the ResponseEvaluation Criteria in Solid Tumors.9 Response rate, PFS, and
overall survival time were analyzed with an intention-to-treat
principle. PFS time and overall survival time were analyzed
using the Kaplan-Meier estimation method and log-rank test.
PFS was calculated from the date of initiation of treatment to
the date of disease progression or death from any cause. If
disease progression had not occurred by the time of this anal-
ysis, PFS was considered to have been censored at the time of
the last follow-up visit. Survival time was measured from the
date of the initiation of treatment to the date of death. Survival
time was considered to have been censored at the last follow-up
time if death had not occurred. The comparisons of clinical
characteristics, response rates, and severity of treatment-related
toxicity were performed using the c2 analysis. The SPSS
(SPSS Inc., Chicago, IL, USA) statistical program was used.
3. Results
One hundred and twenty-three patients with Stage IV
NSCLC who had progressive disease from previous one line of
platinum-based chemotherapy treatment and one line of
EGFR-TKI treatment were treated during this period. The
clinical characteristics of these patients are listed in Table 1.
Except for 11 patients, all had adenocarcinoma of histologic
type. There was no difference in clinical characteristics
between patients who received pemetrexed as third- or fourth-
line treatment, docetaxel as third- or fourth-line treatment, or
between pemetrexed and docetaxel, in terms of age, sex,
performance status, histology, first-line chemotherapeutic
agent and their response, and type of EGFR-TKI and their
response or not.
Median treatment cycles numbered 4 in third- and fourth-
line pemetrexed treatment, and also in docetaxel treatment.
Treatment-related toxicities were few and mild in degree when
pemetrexed was used as third- or fourth-line treatment. Grade
3 or 4 toxicities included 2 leukopenia and 4 neutropenia when
pemetrexed was used as third-line treatment (n ¼ 42), and
1 anemia, 4 leukopenia, 8 neutropenia, 2 thrombocytopenia,
1 fatigue when pemetrexed was used as fourth-line treatment
(n ¼ 43). There was no statistically significant difference in
toxicity profiles (both hematological and non-hematological)
between third-line or fourth-line pemetrexed treatments. Two
patients in third-line treatment needed packed red blood cell
blood transfusion during their treatment period, whereas 7
patients in fourth-line treatment needed packed red blood cell
blood transfusion ( p ¼ 0.424). One patient in fourth-line
treatment needed granulocyte colony-stimulating factor
(G-CSF) support. There was also no statistically significant
difference in toxicity profiles (both hematological and non-
hematological) between third- (n ¼ 21) or fourth-line (n ¼ 17)
docetaxel treatment. When considering pemetrexed or doce-
taxel used as fourth-line treatment, more neutropenia
( p ¼ 0.04), alopecia ( p ¼ 0.004), and G-CSF support
( p ¼ 0.032) was noted in the docetaxel arm. No toxic death
occurred in these 123 patients.
Nineteen of 123 patients had partial response to the treat-
ment, with an overall objective response rate of 15.4%,
Table 1
Patient characteristics of 123 non-small-cell lung cancer patients who received pemetrexed or docetaxel as third- or fourth-line treatment
Patient number Pemetrexed (n ¼ 85) Docetaxel (n ¼ 38) pa
Third line Fourth line Third line Fourth line Pthird versus fourth Dthird versus fourth Pfourth
versus Dfourth
Age Mean 60 63 66 61 0.36 0.203 0.183
Sex Male/female 25/17 24/19 13/8 9/8 0.729 0.578 1
WHO performance status 0 1 1 2 0 0.998 0.418 0.799
1 30 31 14 13
2 11 11 5 4
Histology Adenocarcinoma 36 38 21 17 0.553 1 0.34
Squamous cell carcinoma 3 1 0 0
Type not specified 3 4 0 0
First-line regimen Vinorelbine 15 23 9 5 0.053 0.803 0.342
Taxane 22 11 9 8
Gemcitabine 5 9 3 4
Response to first-line chemo Yes 8 15 2 3 0.1 0.461 0.228
No 34 28 19 14
EGFR-TKI Gefitinib 26 34 12 10 0.082 0.917 0.193
Erlotinib 16 9 9 7
Response to EGFR-TKI Yes 12 10 3 3 0.576 0.778 0.74
No 30 33 18 14
a Pearson two-sided c2 test.
EGFR-TKI ¼ epidermal growth factor receptoretyrosine kinase inhibitor; WHO ¼ World Health Organization.
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patients in fourth-line pemetrexed (11.6%), 2 patients in third-
line docetaxel (9.5%), and 2 patients in fourth-line docetaxel
(11.8%). There was no statistically significant difference in
response rate between third- and fourth-line pemetrexed, third-
and fourth-line docetaxel, or when pemetrexed or docetaxel
was used as fourth-line treatment (Table 2). The disease
control rates were 57.1%, 58.1%, 57.1%, and 70.6%, respec-
tively, in third-line pemetrexed, fourth-line pemetrexed,
third-line docetaxel, and fourth-line docetaxel.
The median PFSs in 85 patients who received pemetrexed
therapy were 2.6 months [95% confidence interval (CI) 0e5.4
months] and 3.8 months (95% CI 1.2e6.5 months), respec-
tively, for third- and fourth-line pemetrexed treatment
( p ¼ 0.4168, Fig. 1). The median survivals were 13.4 months
(95% CI 8.5e18.4 months) and 12.2 months (95% CI
8.8e15.5 months), respectively ( p ¼ 0.8507, Fig. 2). TheTable 2
Efficacy of pemetrexed and docetaxel in third- and fourth-line chemotherapy







Type of response, number PR 10 5 2
SD 14 20 10
PD 18 18 9
Median progression-free survival (mo) 2.6 3.8 3.8
Median survival (mo) 13.4 12.2 13.2
a Pearson two-sided c2 test for comparison of type of response, log-rank test fo
PD ¼ progressive disease; PR ¼ partial response; SD ¼ stable disease.1-year survival rates were 53.9% and 50.1%, respectively.
There was also no difference in PFS and overall survival time
in patients who received docetaxel as third- or fourth-line
treatment (Table 2). Median PFSs of 60 patients who received
pemetrexed (n ¼ 43) or docetaxel (n ¼ 17) as fourth-line
therapy was 3.8 months (95% CI 1.2e6.5 months) in peme-
trexed and 4.8 months (95% CI 1.7e8 months), respectively
( p ¼ 0.6973, Fig. 3). The median survivals were 12.2 months
(95% CI 8.8e15.5 months) in fourth-line pemetrexed and 13
months (95% CI 8.6e17.4), respectively ( p ¼ 0.7833, Fig. 4).
4. Discussion
Docetaxel and pemetrexed had been recommended as stan-
dard second-line chemotherapy when patients had disease
progression after first-line chemotherapy. With more frequent





Pthird versus fourth Dthird versus fourth Pfourth
versus Dfourth
2 0.257 0.694 0.65
10
5
4.8 0.4168 0.8815 0.6973
13 0.8507 0.9645 0.7833
r comparison of progression-free survival.
Fig. 1. Progression-free survival (PFS) of 85 Stage IV non-small-cell lung cancer patients who received pemetrexed as third-line (n ¼ 42, Censor 12) or fourth-line
therapy (n ¼ 43, Censor 6). The median PFSs were 2.6 months (95% confidence interval 0e5.4) and 3.8 months (95% confidence interval 1.2e6.5), respectively
( p ¼ 0.4168).
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now reserved for third-line, or even fourth-line treatment, if the
patient has not used pemetrexed or docetaxel as first- or second-
line treatment.
The available data in the last decade are not sufficient to
make a recommendation for or against using a cytotoxic drug
as third-line therapy, not to mention fourth-line treatment. The
American Society of Clinical Oncology suggests that those
patients who have progressive disease after two lines of
systemic treatment should consider clinical trials, experi-
mental treatment, or receive best supportive care.1 In this
retrospective review, a response rate around 15% and controlFig. 2. Survival curve of 85 Stage IV non-small-cell lung cancer patients who receiv
Censor 19). The median survivals were 13.4 months (95% confidence interval 8
( p ¼ 0.8507). The 1-year survival rates were 53.9% and 50.1%, respectively.rate around 60% for third- and fourth-line treatment with
pemetrexed or docetaxel against NSCLC is very good and
similar to the efficacy of pemetrexed or docetaxel used in the
second-line setting. Thus, it is worthwhile to treat previously
platinum-treated and EGFR-TKI treated NSCLC patients with
one of these two agents, if they have never been exposed to
pemetrexed or docetaxel. Furthermore, the toxicity profiles
showed that these agents are still relatively safe when used in
third- or fourth-line treatment.
Based on this retrospective data, there were no statistical
differences in toxicity profiles, disease response rate and
control rate, and survival data (including PFS and overalled pemetrexed as third-line (n ¼ 42, Censor 22) or fourth-line therapy (n ¼ 43,
.5e18.4) and 12.2 months (95% confidence interval 8.8e15.5), respectively
Fig. 3. Progression-free survival (PFS) of 60 Stage IV non-small-cell lung cancer patients who received pemetrexed (n ¼ 43) or docetaxel (n ¼ 17) as fourth-line
therapy. The median PFSs were 3.8 months (Censor 6, 95% confidence interval 1.2e6.5) in pemetrexed and 4.8 months (Censor 3, 95% confidence interval 1.7e8),
respectively ( p ¼ 0.6973).
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fourth-line treatment. Thus, the decision of which agent to be
used first will depend on previously exposed chemotherapeutic
agents (not to use again if already used as first- or second-line
treatment), and histology (pemetrexed is preferred for non-
squamous cell NSCLC, whereas docetaxel is suggested for
squamous cell NSCLC).10,11 However, docetaxel used in
fourth-line treatment had a higher incidence of severe neu-
tropenia and more frequent need of G-CSF support compared
with pemetrexed in fourth-line treatment. Thus, patients should
be carefully followed up if docetaxel is given as fourth-line
chemotherapy. Because most patients who can receive third-Fig. 4. Survival curve of 60 Stage IV non-small-cell lung cancer patients who rec
median survivals were 12.2 months (Censor 19, 95% confidence interval 8.8e15.5
respectively ( p ¼ 0.7833).or fourth-line treatment have adenocarcinoma, such as 112
of 123 (91.1%) in the present study who had adenocarcinoma,
pemetrexed will be the preferred choice for third-line treatment
in most patients if they have not received pemetrexed as first-
line treatment. In such an instance, docetaxel will be delayed to
fourth-line treatment and should be given carefully.
With advances in modern medicine and supportive care,
lung cancer patients’ general condition frequently remains
robust even after they have had disease progression after two
lines of treatment. In view of reasonable response rate and
control rate, PFS was not inferior or similar to those agents
used in second-line treatment, and relatively long medianeived pemetrexed (n ¼ 43) or docetaxel (n ¼ 17) as fourth-line therapy. The
) in pemetrexed and 13 months (Censor 8, 95% confidence interval 8.6e17.4),
214 Y.-M. Chen et al. / Journal of the Chinese Medical Association 74 (2011) 209e214survival time, use of pemetrexed or docetaxel in the third-line
or fourth-line setting is encouraged if the patient’s perfor-
mance status is still good, between 0 and 2 and with adequate
systemic organ functions. A prospective study is needed to
better clarify the roles of pemetrexed or docetaxel in third-line
or fourth-line treatment.References
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